If GILD drops the price of its HCV drugs 97% and treats 150,000,000 infected globally for $2.500/cure....HCV doesn't exist in 2 years, but GILD will have paid out $240/share in dividends ..Board has fiduciary duty
Miravirsen is a mir-122 inhibitor similar in principal to Rg-101 that was also being developed in San Diego....Roche bought Sabtaris for $485M......At this point I think one of the big biotechs should step in and pick up RGLS on the cheap.
We should like to analyse our experience of renal failure in association
with jaundice during the years 1956-1964 at Hammersmith Hospital.
During this period 384 patients have required dialysis treatment
for acute or acute on chronic renal failure, and of these 81, or 21% have
been jaundiced, defined as a serum bilirubin over l. 5 mg. %. A further
five patients were reported to be clinically icteric, but as the serum
bilirubin was not measured they have not been included. We have omitted
from consideration all patients with renal failure who recovered on conservative
management alone, all patients who died of their primary disease
before dialysis was considered necessary, or who died before dialysis could
be undertaken. Thus we are only considering here a group of patients
with severe renal failure whose blood ureas all exceeded 350 mg. % at
some point in their illness.
The 81 patients have been subdivided into 12 groups depending on
the predominant aetiology of the jaundice ( Table I ). There is some degree
of overlap in the groups as there may be mild haemolysis in some obstetric
patients, and infection was obviously present in some patients with obstructive